DAFTAR PUSTAKA

Abedalthagafi, M., Bi, W.L., Aizer, A.A., Merrill, P.H., Brewster, R., Agarwalla,
P.K., Listewnik, M.L., Dias-Santagata, D., Thorner, A.R., Van Hummelen,
P., Brastianos, P.K., Reardon, D.A., Wen, P.Y., Al-Mefty, O., Ramkissoon,
S.H., Folkerth, R.D., Ligon, K.L., Ligon, A.H., Alexander, B.M., Dunn, I.F.,
Beroukhim, R. and Santagata, S., 2016. 'Oncogenic PI3K mutations are as
common as AKT1 and SMO mutations in meningioma'. Neuro-Oncology,
vol. 18, no. 5, pp. 649–655.
Alruwaili, A. A., & De Jesus, O. (2022). 'Meningioma'. Treasure Island (FL):
StatPearls Publishing; 2022 Jan–. PMID: 32809373.
Andersen, L., Friis, S., Hallas, J., Ravn, P., Schrøder, H. D., & Gaist, D. (2013).
'Hormone replacement therapy increases the risk of cranial meningioma'.
European Journal of Cancer, 49(15), 3303–3310.
Baziad Ali. (2008). 'Kontrasepsi Hormonal'. Jakarta: Bina Pustaka Sarwono
Prawirohardjo.
Brenner, A. V., Sugiyama, H., Preston, D. L., Sakata, R., French, B., Sadakane,
A., Cahoon, E. K., Utada, M., Mabuchi, K., & Ozasa, K. (2020). 'Radiation
risk of central nervous system tumors in the Life Span Study of atomic bomb
survivors', 1958-2009. European journal of epidemiology, 35(6), 591–600.
Buerki, R. A., Horbinski, C. M., Kruser, T., Horowitz, P. M., James, C. D., &
Lukas, R. V. (2018). 'An overview of meningiomas'. Future Oncology
(London, England), 14(21), 2161–2177.
Carvalho, G. T. C. de, Silva-Martins, W. C. da, Magalhães, K. C. S. F. de, Nunes,
C. B., Soares, A. N., Tafuri, L. S. de A., & Simões, R. T. (2020).
'Recurrence/Regrowth in Grade I Meningioma: How to Predict?' Frontiers in
Oncology, 10(August), 1–15.
Choy, W., Kim, W., Nagasawa, D., Stramotas, S., Yew, A., Gopen, Q., Parsa, A.
T., & Yang, I. (2011). 'The molecular genetics and tumor pathogenesis of
meningiomas and the future directions of meningioma treatments'.
Neurosurgical focus, 30(5), E6.
Clark, V.E., Erson-Omay, E.Z., Serin, A., Yin, J., Cotney, J., Özduman, K.,
Avşar, T., Li, J., Murray, P.B., Henegariu, O., Yilmaz, S., Günel, J.M.,
Carrión-Grant, G., Yilmaz, B., Grady, C., Tanrikulu, B., Bakircioǧlu, M.,
Kaymakçalan, H., Caglayan, A.O., Sencar, L., Ceyhun, E., Atik, A.F.,
Bayri, Y., Bai, H., Kolb, L.E., Hebert, R.M., Omay, S.B., Mishra-Gorur, K.,
Choi, M., Overton, J.D., Holland, E.C., Mane, S., State, M.W., Bilgüvar, K.,
Baehring, J.M., Gutin, P.H., Piepmeier, J.M., Vortmeyer, A., Brennan,
C.W., Pamir, M.N., Kiliç, T., Lifton, R.P., Noonan, J.P., Yasuno, K. and
Günel, M., 2013. 'Genomic analysis of non-NF2 meningiomas reveals
mutations in TRAF7, KLF4, AKT1, and SMO'. Science, vol. 339, no. 6123,
pp. 1077–1080.
Clark, V.E., Harmancl, A.S., Bai, H., Youngblood, M.W., Lee, T.I., Baranoski,
J.F., Ercan-Sencicek, A.G., Abraham, B.J., Weintraub, A.S., Hnisz, D.,
Simon, M., Krischek, B., Erson-Omay, E.Z., Henegariu, O., Carrión-Grant,
G., Mishra-Gorur, K., Durán, D., Goldmann, J.E., Schramm, J.,
Goldbrunner, R., Piepmeier, J.M., Vortmeyer, A.O., Günel, J.M., Bilgüvar,

57
58

K., Yasuno, K., Young, R.A. and Günel, M., 2016. 'Recurrent somatic
mutations in POLR2A define a distinct subset of meningiomas'. Nature
Genetics, vol. 48, no. 10, pp. 1253–1259.
Claus, E. B., Calvocoressi, L., Bondy, M. L., Schildkraut, J. M., Wiemels, J. L., &
Wrensch, M. (2012). 'Dental x-rays and risk of meningioma'. Cancer,
118(18), 4530–4537.
Claus, E. B., & Morrison, L. (2011). 'Epidemiology of Meningiomas'. In Al-
Mefty’s Meningioma (2nd ed., pp. 35–39). New York: Thieme.
Coy, S., Rashid, R., Stemmer-Rachamimov, A., & Santagata, S. (2020). 'An
update on the CNS manifestations of neurofibromatosis type 2'. Acta
neuropathologica, 139(4), 643–665.
Delgado-López, P. D., Cubo-Delgado, E., González-Bernal, J. J., & Martín-
Alonso, J. (2020). 'A Practical overview on the molecular biology of
meningioma'. Current Neurology and Neuroscience Reports, 20(12).
DeMonte, F., McDermott, M. W., & Al-Mefty, O. (2011). 'Al-Mefty’s
Meningiomas (2nd ed.)'. New York: Thieme.
Dewata, L., Prasetyo, B., Yuliati, A., & Wahyuhadi, J. (2017). 'Hormonal
contraceptive exposure and risk factors for meningioma in Soetomo hospital
2012–2016'. Advanced Science Letters, 23(4), 3291-3294
Dresser, L., Yuen, C. A., Wilmington, A., Walker, M., Vogel, T. J., Merrell, R.
T., & Kamson, D. O. (2020). 'Estrogen hormone replacement therapy in
incidental intracranial meningioma: a growth-rate analysis'. Scientific
Reports, 10(1), 17960.
Fan, Z.-X., Shen, J., Wu, Y.-Y., Yu, H., Zhu, Y., & Zhan, R.-Y. (2013). 'Hormone
replacement therapy and risk of meningioma in women: a meta-analysis'.
Cancer Causes & Control, 24(8), 1517–1525.
Fekadie, M., Seifu, D., Kumpi, S., & Kokeb, A. (2016). 'Effect of depo-
medroxyprogesterone acetate ( DMPA ) on lipid metabolism'. International
Journal of Research in Biotechnology and Biochemistry. 6(1), 6-11
Guevara, P., Escobar-Arriaga, E., Saavedra-Perez, D., Martinez-Rumayor, A.,
Flores-Estrada, D., Rembao, D., Calderon, A., Sotelo, J., & Arrieta, O.
(2010). 'Angiogenesis and expression of estrogen and progesterone receptors
as predictive factors for recurrence of meningioma'. Journal of neuro-
oncology, 98(3), 379–384.
Hadidy, A. M., Nadi, M. M., Ahmad, T. M., Al-Hussaini, M. A., Al-Abaddi, A.
A., Musharbash, A. F., & Maani, W. S. (2010). 'Descriptive epidemiological
analysis, MRI signals intensity and histopathological correlations of
meningiomas'. Neurosciences (Riyadh, Saudi Arabia), 15(1), 11–14.
Hage, M., Plesa, O., Lemaire, I., & Raffin Sanson, M. L. (2022). 'Estrogen and
progesterone therapy and meningiomas'. Endocrinology, 163(2).
Harter, P. N., Braun, Y., & Plate, K. H. (2017). 'Classification of meningiomas-
advances and controversies'. Chinese Clinical Oncology, 6(Suppl 1), S2.
Holleczek, B., Zampella, D., Urbschat, S., Sahm, F., von Deimling, A., Oertel, J.,
& Ketter, R. (2019). 'Incidence, mortality and outcome of meningiomas: A
population-based study from Germany'. Cancer Epidemiology, 62, 101562.
Huntoon, K., Toland, A. M. S., & Dahiya, S. (2020). 'Meningioma: A Review of
clinicopathological and molecular aspects'. Frontiers in Oncology,
10(October), 1–14.
59

Ji, Y., Rankin, C., Grunberg, S., Sherrod, A. E., Ahmadi, J., Townsend, J. J.,
Feun, L. G., Fredericks, R. K., Russell, C. A., Kabbinavar, F. F., Stelzer, K.
J., Schott, A., & Verschraegen, C. (2015). 'Double-blind phase III
randomized trial of the antiprogestin agent mifepristone in the treatment of
unresectable meningioma: SWOG S9005'. Journal of clinical oncology:
official journal of the American Society of Clinical Oncology, 33(34), 4093–
4098.
Kalamarides, M., Stemmer-Rachamimov, A.O., Niwa-Kawakita, M., Chareyre,
F., Taranchon, E., Han, Z.Y., Martinelli, C., Lusis, E.A., Hegedus, B.,
Gutmann, D.H. and Giovannini, M. (2011). 'Identification of a progenitor
cell of origin capable of generating diverse meningioma histological
subtypes'. Oncogene, 30(20), 2333–2344.
Karsy, M., Azab, M. A., Abou-Al-Shaar, H., Guan, J., Eli, I., Jensen, R. L., &
Ormond, D. R. (2018). 'Clinical potential of meningioma genomic insights:
A practical review for neurosurgeons'. Neurosurgical Focus, 44(6), 1–7.
Katz, M., Newmark, R. L., Aronstam, A., O’Grady, N., Strome, S., Rafie, S., &
Karlin, J. (2020). 'An implementation project to expand access to self-
administered depot medroxyprogesterone acetate (DMPA)'. Contraception,
102(6), 392–395.
Lanzola, E. L., & Ketvertis, K. (2022). 'Intrauterine Device'. Treasure Island (FL):
StatPearls Publishing; 2022 Jan–. PMID: 32491335
Lassie, N., & Supartoto, A. (2016). 'Progesterone receptor expression in
histopathological subtypes of beningn orbitocranial meningiomas'.
Ophthalmol Ina, 42(1), 91–96.
Lee, Y. S., & Lee, Y. S. (2020). 'Molecular characteristics of meningiomas'.
Journal of Pathology and Translational Medicine, 54(1), 45–63.
Louis, D.N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D.,
Cavenee, W.K., Ohgaki, H., Wiestler, O.D., Kleihues, P. and Ellison, D.W.
(2016). 'The 2016 World Health Organization classification of tumors of the
central nervous system: a summary'. Acta Neuropathologica, 131(6), 803–
820.
M Taghipour, SM Rakei, A Monabati, M. N.-N. (2009). 'The role of estrogen and
progesterone receptors in grading of the malignancy of meningioma'.
Journal of Clinical Psychology, 2(1), 163–167.
Maiuri, F., Mariniello, G., de Divitiis, O., Esposito, F., Guadagno, E., Teodonno,
G., Barbato, M., & Del Basso De Caro, M. (2021). 'Progesterone receptor
expression in meningiomas: pathological and prognostic implications'.
Frontiers in oncology, 11, 611218.
Malueka, R. G., Hartanto, R. A., Setyawan, N. H., Fauzi, D., Damarjati, K. R.,
Rismawan, A., Septianastiti, M. A., Wicaksono, A. S., Dananjoyo, K.,
Basuki, E., Asmedi, A., & Dwianingsih, E. K. (2022). 'Association of
hormonal contraception with meningioma location in Indonesian patients'.
Asian Pacific journal of cancer prevention: APJCP, 23(3), 1047–1051.
Marosi, C., Hassler, M., Roessler, K., Reni, M., Sant, M., Mazza, E., & Vecht, C.
(2008). 'Meningioma'. Critical Reviews in Oncology/Hematology, 67(2),
153–171.
Matahari, R., Utami, F. P., & Sugiharti, S. (2018). 'Buku Ajar Keluarga
Berencana dan Kontrasepsi (I)'. Jogjakarta: Pustaka Ilmu.
60

Och, W., Szmuda, T., Sikorska, B., Springer, J., Jaskólski, D., Zakrzewska, M., &
Liberski, P. P. (2016). 'Recurrence-associated chromosomal anomalies in
meningiomas: Single-institution study and a systematic review with meta-
analysis'. Neurologia i Neurochirurgia Polska, 50(6), 439–448.
Ogasawara, C., Philbrick, B. D., & Adamson, D. C. (2021). 'Meningioma: A
review of epidemiology, pathology, diagnosis, treatment, and future
directions'. Biomedicines, 9(3), 319.
Olar, A., Wani, K. M., Wilson, C. D., Zadeh, G., DeMonte, F., Jones, D. T.,
Pfister, S. M., Sulman, E. P., & Aldape, K. D. (2017). 'Global epigenetic
profiling identifies methylation subgroups associated with recurrence-free
survival in meningioma'. Acta neuropathologica, 133(3), 431–444
Ostrom, Q. T., Cioffi, G., Gittleman, H., Patil, N., Waite, K., Kruchko, C., &
Barnholtz-Sloan, J. S. (2019). 'CBTRUS Statistical Report: Primary brain
and other central nervous system tumors diagnosed in the United States in
2012-2016.' Neuro-Oncology, 21, V1–V100.
Park, J.-S., Sade, B., Oya, S., Kim, C. G., & Lee, J. H. (2014). 'The influence of
age on the histological grading of meningiomas.' Neurosurgical Review,
37(3), 425–429
Pawloski, J. A., Fadel, H. A., Huang, Y.-W., & Lee, I. Y. (2021). Genomic
biomarkers of meningioma: A Focused Review. International Journal of
Molecular Sciences, 22(19).
Perry, A., Gutmann, D. H., & Reifenberger, G. (2004). 'Molecular pathogenesis of
meningiomas'. Journal of Neuro-Oncology, 70(2), 183–202.
Petrilli, A. M., & Fernández-Valle, C. (2016). 'Role of Merlin/NF2 inactivation in
tumor biology'. Oncogene, 35(5), 537–548.
Peyre, M., Gaillard, S., de Marcellus, C., Giry, M., Bielle, F., Villa, C., Boch,
A.L., Loiseau, H., Baussart, B., Cazabat, L., Raffin-Sanson, M.L., Sanson,
M. and Kalamarides, M. (2018). 'Progestin-associated shift of meningioma
mutational landscape'. Annals of Oncology, 29(3), 681–686.
Preusser, M., Brastianos, P. K., & Mawrin, C. (2018). 'Advances in meningioma
genetics: Novel therapeutic opportunities'. Nature Reviews Neurology, 14(2),
106–115.
Proctor, D. T., Ramachandran, S., Lama, S., & Sutherland, G. R. (2018). 'Towards
molecular classification of meningioma: evolving treatment and diagnostic
paradigms'. World Neurosurgery, 119, 366–373.
Qi, Z. Y., Shao, C., Huang, Y. L., Hui, G. Z., Zhou, Y. X., & Wang, Z. (2013).
'Reproductive and exogenous hormone factors in relation to risk of
meningioma in women: A meta-analysis'. PLoS ONE, 8(12).
Regidor, P. A. (2018). 'The clinical relevance of progestogens in hormonal
contraception: Present status and future developments'. Oncotarget, 9(77),
34628–34638.
Riemenschneider, M. J., Perry, A., & Reifenberger, G. (2006). 'Histological
classification and molecular genetics of meningiomas'. The Lancet
Neurology, 5(12), 1045–1054.
Rockhill, J., Mrugala, M., & Chamberlain, M. C. (2007). 'Intracranial
meningiomas: an overview of diagnosis and treatment'. Neurosurgical Focus,
23(4), E1.
Roux, A., Tauziede-espariat, A., Zanello, M., Gareton, A., & Malaize, H. (2020).
61

'Symptomatic progestin-associated atypical grade II meningioma . A first

case report'. Neurochirurgie, 66(3), 174–178.
Schindler, A. E., Campagnoli, C., Druckmann, R., Huber, J., Pasqualini, J. R.,
Schweppe, K. W., & Thijssen, J. H. H. (2008). 'Classification and
pharmacology of progestins'. Maturitas, 46(SUPPL. 1), 7.
Schreiber, C. A., & Barnhart, K. (2019). 'Contraception''. In J. F. Strauss & R. L.
Barbieri (Eds.), Yen and Jaffe’s Reproductive Endocrinology (Eighth
Edition) (Eighth Edi, pp. 962-978.e4). Philadelphia: Elsevier.
Shah, D. S., Sanan, A., Morell, A. A., Eichberg, D. G., Shah, A. H., Luther, E.,
Lu, V. M., Elarjani, T., Higgins, D., Patel, N. V., Jagid, J. R., Ivan, M. E., &
Komotar, R. J. (2022). 'Traumatic brain injury and subsequent brain tumor
development: a systematic review of the literature'. Neurosurgical review,
45(5), 3003–3018.
Shayanfar, N., Mashayekh, M., & Mohammadpour, M. (2010). 'Expression of
progestrone receptor and proliferative marker ki 67 in various grades of
meningioma'. Acta Medica Iranica, 48(3), 142–147.
Supartoto, A., Sasongko, M. B., Respatika, D., & Mahayana, I. T. (2019).
'Relationships Between Neurofibromatosis-2 , Progesterone Receptor
Expression , the Use of Exogenous Progesterone , and Risk of Orbitocranial
Meningioma in Females'. Frontiers in Oncology, 8(January), 1–7.
Takahashi, H., Cornish, A.J., Sud, A., Law, P.J., Disney-Hogg, L., Calvocoressi,
L., Lu, L., Hansen, H.M., Smirnov, I., Walsh, K.M., Schramm, J., Hoffmann,
P., Nöthen, M.M., Jöckel, K.H., Schildkraut, J.M., Simon, M., Bondy, M.,
Wrensch, M., Wiemels, J.L., Claus, E.B., Turnbull, C. and Houlston, R.S.
(2019). 'Mendelian randomization provides support for obesity as a risk
factor for meningioma. Scientific Reports. 9(1), 309.
Telugu, R., Chowhan, A., Rukmangadha, N., Patnayak, R., Phaneendra, B.,
Mowliswara Prasad, B., & Reddy, M. (2020). 'Estrogen and progesterone
receptor in meningiomas: An immunohistochemical analysis YR -
2020/10/1'. Journal of Cancer Research and Therapeutics, 16(6), 1482–1487
Wahyuhadi, J., Heryani, D., & Basuki, H. (2018). 'Risk of meningioma associated
with exposure of hormonal contraception. A case control study'. Majalah
Obstetri & Ginekologi, 26(1), 36.
Wahyuhadi, J. and Rusdi, F. P. (2022) ‘Association between hormonal
contraception with histopathology grading of meningioma’, Nat. Volatiles &
Essent. Oils, 9(1), pp. 1583–1592.
Wahyuhadi, J., Utama, A. S., Arifin, M., Al Fauzi, A., Lestari, P., Kusumastuti,
K., et al. (2022) ‘Factors predicting complications, neurologic deterioration
and mortality for patients with meningioma surgery: An observational study’,
F1000Research, 11, p. 1104.
Walsh, K. M. (2020). 'Epidemiology of meningiomas'. Handbook of Clinical
Neurology, 169, 3–15.
Wiemels, J., Wrensch, M., & Claus, E. B. (2010). 'Epidemiology and etiology of
meningioma'. Journal of neuro-oncology, 99(3), 307–314.
Wigertz, A., Lönn, S., Mathiesen, T., Ahlbom, A., Hall, P., & Feychting, M.
(2006). Risk of brain tumors associated with exposure to exogenous female
sex hormones. American Journal of Epidemiology, 164(7), 629–636.
62

Wolfsberger, S., Doostkam, S., Boecher-Schwarz, H.-G., Roessler, K., van

Trotsenburg, M., Hainfellner, J. A., & Knosp, E. (2004). Progesterone-
receptor index in meningiomas: correlation with clinico-pathological
parameters and review of the literature. Neurosurgical Review, 27(4), 238–
245.